Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study.
| Author | |
|---|---|
| Abstract |
:
High-grade serous ovarian carcinoma is characterised by TP53 mutations, DNA repair defects, and genomic instability. We hypothesised that prexasertib (LY2606368), a cell cycle checkpoint kinase 1 and 2 inhibitor, would be active in BRCA wild-type disease. |
| Year of Publication |
:
2018
|
| Journal |
:
The Lancet. Oncology
|
| Date Published |
:
2018
|
| ISSN Number |
:
1470-2045
|
| URL |
:
http://linkinghub.elsevier.com/retrieve/pii/S1470-2045(18)30009-3
|
| DOI |
:
10.1016/S1470-2045(18)30009-3
|
| Short Title |
:
Lancet Oncol
|
| Download citation |
